J Hans Devries

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2010691/publications.pdf

Version: 2024-02-01

76326 30922 11,225 115 40 102 citations h-index g-index papers 117 117 117 9422 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Glucagon-like peptide-1, a matter of taste?. Reviews in Endocrine and Metabolic Disorders, 2021, 22, 763-775.	5.7	8
2	ADO09, a coâ€formulation of the amylin analogue pramlintide and the insulin analogue A21C, lowers postprandial blood glucose versus insulin lispro in type 1 diabetes. Diabetes, Obesity and Metabolism, 2021, 23, 961-970.	4.4	18
3	Preoperative considerations of new long-acting glucagon-like peptide-1 receptor agonists in diabetes mellitus. British Journal of Anaesthesia, 2021, 126, 567-571.	3.4	21
4	Consequences of the COVID-19 pandemic for patients with metabolic diseases. Nature Metabolism, 2021, 3, 289-292.	11.9	33
5	Cover Image, Volume 23, Issue 4. Diabetes, Obesity and Metabolism, 2021, 23, .	4.4	O
6	Long-term quality of life and exocrine and endocrine insufficiency after pancreatic surgery: a multicenter, cross-sectional study. Hpb, 2021, 23, 1722-1731.	0.3	10
7	Effects of Hyperglycemia and Diabetes Mellitus on Coagulation and Hemostasis. Journal of Clinical Medicine, 2021, 10, 2419.	2.4	40
8	The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2021, 44, 2589-2625.	8.6	244
9	The management of type 1 diabetes in adults. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2021, 64, 2609-2652.	6.3	128
10	Less common types of diabetes mellitus: Incidence and glucose control in the perioperative setting. Journal of Clinical Anesthesia, 2021, 75, 110460.	1.6	2
11	Fully Closed Loop Glucose Control With a Bihormonal Artificial Pancreas in Adults With Type 1 Diabetes: An Outpatient, Randomized, Crossover Trial. Diabetes Care, 2021, 44, 836-838.	8.6	44
12	COVID-19 and metabolic disease: mechanisms and clinical management. Lancet Diabetes and Endocrinology,the, 2021, 9, 786-798.	11.4	155
13	A Classification Algorithm for Types of Diabetes in Chronic Pancreatitis Using Epidemiological Characteristics. Pancreas, 2021, 50, 1407-1414.	1.1	0
14	Liraglutide for perioperative management of hyperglycaemia in cardiac surgery patients: a multicentre randomized superiority trial. Diabetes, Obesity and Metabolism, 2020, 22, 557-565.	4.4	28
15	Sex differences in cardiometabolic risk factors, pharmacological treatment and risk factor control in type 2 diabetes: findings from the Dutch Diabetes Pearl cohort. BMJ Open Diabetes Research and Care, 2020, 8, e001365.	2.8	17
16	Prophylactic total pancreatectomy in individuals at high risk of pancreatic ductal adenocarcinoma (PROPAN): systematic review and shared decisionâ€making programme using decision tables. United European Gastroenterology Journal, 2020, 8, 865-877.	3.8	11
17	Effects of Liraglutide on Myocardial Function After Cardiac Surgery: A Secondary Analysis of the Randomised Controlled GLOBE Trial. Journal of Clinical Medicine, 2020, 9, 673.	2.4	4
18	Practical recommendations for the management of diabetes in patients with COVID-19. Lancet Diabetes and Endocrinology, the, 2020, 8, 546-550.	11.4	680

#	Article	IF	CITATIONS
19	The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Human Reproduction Update, 2019, 25, 504-517.	10.8	34
20	Outcome and long-term quality of life after total pancreatectomy (PANORAMA): a nationwide cohort study. Surgery, 2019, 166, 1017-1026.	1.9	43
21	SUGAR-DIP trial: oral medication strategy versus insulin for diabetes in pregnancy, study protocol for a multicentre, open-label, non-inferiority, randomised controlled trial. BMJ Open, 2019, 9, e029808.	1.9	6
22	Acceptance of the Artificial Pancreas: Comparing the Effect of Technology Readiness, Product Characteristics, and Social Influence Between Invited and Self-Selected Respondents. Journal of Diabetes Science and Technology, 2019, 13, 899-909.	2.2	9
23	Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in Range. Diabetes Care, 2019, 42, 1593-1603.	8.6	2,101
24	Use of fastâ€acting insulin aspart in insulin pump therapy in clinical practice. Diabetes, Obesity and Metabolism, 2019, 21, 2039-2047.	4.4	41
25	Efficacy of total pancreatectomy with islet autotransplantation on opioid and insulin requirement in painful chronic pancreatitis: A systematic review and meta-analysis. Surgery, 2019, 166, 263-270.	1.9	23
26	Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2. Diabetes, Obesity and Metabolism, 2019, 21, 1634-1641.	4.4	14
27	Better glycaemic control with BioChaperone glargine lispro coâ€formulation than with insulin lispro Mix25 or separate glargine and lispro administrations after a test meal in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 2019, 21, 1570-1575.	4.4	5
28	The association of intravenous insulin and glucose infusion with intensive care unit and hospital mortality: a retrospective study. Annals of Intensive Care, 2019, 9, 29.	4.6	8
29	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. Diabetes, Obesity and Metabolism, 2019, 21, 1066-1070.	4.4	31
30	The International Diabetes Closed-Loop Study: Testing Artificial Pancreas Component Interoperability. Diabetes Technology and Therapeutics, 2019, 21, 73-80.	4.4	13
31	Comparison of perioperative glucose regulation in patients with type 1 vs type 2 diabetes mellitus: A retrospective crossâ€sectional study. Acta Anaesthesiologica Scandinavica, 2019, 63, 314-321.	1.6	5
32	Dayâ€toâ€day fasting selfâ€monitored blood glucose variability is associated with risk of hypoglycaemia in insulinâ€treated patients with type 1 and type 2 diabetes: A post hoc analysis of the SWITCH Trials. Diabetes, Obesity and Metabolism, 2019, 21, 622-630.	4.4	15
33	A randomized, multicentre trial evaluating the efficacy and safety of fastâ€acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). Diabetes, Obesity and Metabolism, 2019, 21, 961-967.	4.4	59
34	Continuous glucose monitoring during diabetic pregnancy (GlucoMOMS): A multicentre randomized controlled trial. Diabetes, Obesity and Metabolism, 2018, 20, 1894-1902.	4.4	77
35	Neonatal Hypoglycemia Following Diet-Controlled and Insulin-Treated Gestational Diabetes Mellitus. Diabetes Care, 2018, 41, 1385-1390.	8.6	52
36	Glycemic Effects of a Lowâ€Carbohydrate Enteral Formula Compared With an Enteral Formula of Standard Composition in Critically III Patients: An Open‣abel Randomized Controlled Clinical Trial. Journal of Parenteral and Enteral Nutrition, 2018, 42, 1035-1045.	2.6	22

#	Article	IF	Citations
37	Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial. Diabetologia, 2018, 61, 780-789.	6.3	42
38	In response to: Metformin for the management of periâ€operative hyperglycaemia. Diabetes, Obesity and Metabolism, 2018, 20, 755-755.	4.4	0
39	The relation between HbA1c and hypoglycemia revisited; a secondary analysis from an intervention trial in patients with type 1 diabetes and impaired awareness of hypoglycemia. Journal of Diabetes and Its Complications, 2018, 32, 100-103.	2.3	8
40	Acceptability of Implantable Continuous Glucose Monitoring Sensor. Journal of Diabetes Science and Technology, 2018, 12, 634-638.	2.2	22
41	The prevalence of cardiovascular autonomic neuropathy and its influence on post induction hemodynamic variables in patients with and without diabetes; A prospective cohort study. PLoS ONE, 2018, 13, e0207384.	2.5	1
42	Systematic review of incretin therapy during peri-operative and intensive care. Critical Care, 2018, 22, 299.	5.8	31
43	Long-Term Effects of Oral Antidiabetic Drugs During Pregnancy on Offspring: A Systematic Review and Meta-analysis of Follow-up Studies of RCTs. Diabetes Therapy, 2018, 9, 1811-1829.	2.5	37
44	Variability of insulin degludec and glargine 300 U/mL: A matter of methodology or just marketing?. Diabetes, Obesity and Metabolism, 2018, 20, 2051-2056.	4.4	5
45	New-onset diabetes after pancreatoduodenectomy: A systematic review and meta-analysis. Surgery, 2018, 164, 6-16.	1.9	27
46	Study protocol of the randomised placebo-controlled GLOBE trial: <i>GL</i> P-1 f <i>o</i> r <i>b</i> rdging of hyperglyca <i>e</i> mia during cardiac surgery. BMJ Open, 2018, 8, e022189.	1.9	8
47	Ultraâ€rapid BioChaperone Lispro improves postprandial blood glucose excursions vs insulin lispro in a 14â€day crossover treatment study in people with type 1 diabetes. Diabetes, Obesity and Metabolism, 2018, 20, 2627-2632.	4.4	31
48	Achieving glycaemic control without weight gain, hypoglycaemia, or gastrointestinal adverse events in type 2 diabetes in the SUSTAIN clinical trial programme. Diabetes, Obesity and Metabolism, 2018, 20, 2426-2434.	4.4	11
49	DPP-4 Inhibitor–Related Pancreatitis: Rare but Real!. Diabetes Care, 2017, 40, 161-163.	8.6	33
50	Higher glucose variability in type 1 than in type 2 diabetes patients admitted to the intensive care unit: A retrospective cohort study. Journal of Critical Care, 2017, 38, 300-303.	2.2	11
51	The artificial pancreasâ€"ready for prime time?. Lancet Diabetes and Endocrinology,the, 2017, 5, 238-239.	11.4	7
52	The haemoglobin glycation index as predictor of diabetes-related complications in the AleCardio trial. European Journal of Preventive Cardiology, 2017, 24, 858-866.	1.8	33
53	Impact of Liraglutide on Amylase, Lipase, and Acute Pancreatitis in Participants With Overweight/Obesity and Normoglycemia, Prediabetes, or Type 2 Diabetes: Secondary Analyses of Pooled Data From the SCALE Clinical Development Program. Diabetes Care, 2017, 40, 839-848.	8.6	49
54	Future of Automated Insulin Delivery Systems. Diabetes Technology and Therapeutics, 2017, 19, S-67-S-72.	4.4	31

#	Article	IF	CITATIONS
55	Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial. Lancet Diabetes and Endocrinology, the, 2017, 5, 355-366.	11.4	288
56	Continuous Glucose Monitoring in Patients with Type 1 Diabetes and Impaired Awareness of Hypoglycemia: Also Effective in Patients with Psychological Distress?. Diabetes Technology and Therapeutics, 2017, 19, 595-599.	4.4	13
57	Venous, Arterialized-Venous, or Capillary Glucose Reference Measurements for the Accuracy Assessment of a Continuous Glucose Monitoring System. Diabetes Technology and Therapeutics, 2017, 19, 609-617.	4.4	10
58	International Consensus on Use of Continuous Glucose Monitoring. Diabetes Care, 2017, 40, 1631-1640.	8.6	1,376
59	Accuracy and Longevity of an Implantable Continuous Glucose Sensor in the PRECISE Study: A 180-Day, Prospective, Multicenter, Pivotal Trial. Diabetes Care, 2017, 40, 63-68.	8.6	141
60	The Clinical Benefits and Accuracy of Continuous Glucose Monitoring Systems in Critically Ill Patients—A Systematic Scoping Review. Sensors, 2017, 17, 146.	3.8	42
61	Outcome Measures for Artificial Pancreas Clinical Trials: A Consensus Report. Diabetes Care, 2016, 39, 1175-1179.	8.6	195
62	Day-and-Night Closed-Loop Glucose Control in Patients With Type 1 Diabetes Under Free-Living Conditions: Results of a Single-Arm 1-Month Experience Compared With a Previously Reported Feasibility Study of Evening and Night at Home. Diabetes Care, 2016, 39, 1151-1160.	8.6	98
63	Retinal neurodegeneration may precede microvascular changes characteristic of diabetic retinopathy in diabetes mellitus. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, E2655-64.	7.1	442
64	A Review of Safety and Design Requirements of the Artificial Pancreas. Annals of Biomedical Engineering, 2016, 44, 3158-3172.	2.5	45
65	Continuous glucose monitoring for patients with type 1 diabetes and impaired awareness of hypoglycaemia (IN CONTROL): a randomised, open-label, crossover trial. Lancet Diabetes and Endocrinology,the, 2016, 4, 893-902.	11.4	284
66	Continuous Glucose Monitoring. Journal of Diabetes Science and Technology, 2016, 10, 1251-1258.	2.2	22
67	Assessing the Accuracy of Continuous Glucose Monitoring (CGM) Calibrated With Capillary Values Using Capillary or Venous Glucose Levels as a Reference. Journal of Diabetes Science and Technology, 2016, 10, 876-884.	2.2	23
68	AP@home. Journal of Diabetes Science and Technology, 2016, 10, 950-958.	2.2	8
69	Perioperative Hyperglycemia and Glucose Variability in Gynecologic Laparotomies. Journal of Diabetes Science and Technology, 2016, 10, 145-150.	2.2	10
70	Use of an Intravascular Fluorescent Continuous Glucose Sensor in ICU Patients. Journal of Diabetes Science and Technology, 2015, 9, 762-770.	2.2	18
71	The longâ€ŧerm effect of energy restricted diets for treating obesity. Obesity, 2015, 23, 1529-1538.	3.0	51
72	Postprandial or Fasting Hyperglycemia: Time to Move On?. Diabetes Technology and Therapeutics, 2015, 17, 441-442.	4.4	1

#	Article	IF	Citations
73	Lowering blood glucose during hip surgery does not influence coagulation activation. BBA Clinical, 2015, 3, 227-232.	4.1	6
74	Accuracy of Intra-arterial and Subcutaneous Continuous Glucose Monitoring in Postoperative Cardiac Surgery Patients in the ICU. Journal of Diabetes Science and Technology, 2015, 9, 663-667.	2.2	23
75	Continuous Intraperitoneal Insulin Infusion Versus Subcutaneous Insulin Therapy in the Treatment of Type 1 Diabetes: Effects on Glycemic Variability. Diabetes Technology and Therapeutics, 2015, 17, 379-384.	4.4	17
76	2 month evening and night closed-loop glucose control in patients with type 1 diabetes under free-living conditions: a randomised crossover trial. Lancet Diabetes and Endocrinology,the, 2015, 3, 939-947.	11.4	189
77	New Long-Acting Insulin Analogs: From Clamp Studies to Clinical Practice. Diabetes Care, 2015, 38, 541-543.	8.6	21
78	Feasibility of a Portable Bihormonal Closed-Loop System to Control Glucose Excursions at Home Under Free-Living Conditions for 48 Hours. Diabetes Technology and Therapeutics, 2014, 16, 131-136.	4.4	69
79	Poor Agreement of Computerized Calculators for Mean Amplitude of Glycemic Excursions. Diabetes Technology and Therapeutics, 2014, 16, 72-75.	4.4	18
80	Study protocol of a randomised controlled trial comparing perioperative intravenous insulin, GIK or GLP-1 treatment in diabetes–PILGRIM trial. BMC Anesthesiology, 2014, 14, 91.	1.8	8
81	Reductions in systolic blood pressure with liraglutide in patients with type 2 diabetes: Insights from a patient-level pooled analysis of six randomized clinical trials. Journal of Diabetes and Its Complications, 2014, 28, 399-405.	2.3	75
82	Insulin treatment guided by subcutaneous continuous glucose monitoring compared to frequent point-of-care measurement in critically ill patients: a randomized controlled trial. Critical Care, 2014, 18, 453.	5.8	80
83	One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA1c target. Journal of Diabetes and Its Complications, 2013, 27, 492-500.	2.3	42
84	Real-Time Improvement of Continuous Glucose Monitoring Accuracy: The smart sensor concept. Diabetes Care, 2013, 36, 793-800.	8.6	86
85	Intensive insulin therapy for type 2 diabetes at diagnosis. Lancet Diabetes and Endocrinology,the, 2013, 1, 3-4.	11.4	7
86	Microcirculation and its relation to continuous subcutaneous glucose sensor accuracy in cardiac surgery patients in the intensive care unit. Journal of Thoracic and Cardiovascular Surgery, 2013, 146, 1283-1289.	0.8	25
87	Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Lancet Diabetes and Endocrinology,the, 2013, 1, 123-131.	11.4	37
88	Glucose Variability: Where It Is Important and How to Measure It. Diabetes, 2013, 62, 1405-1408.	0.6	186
89	Patch Pump Versus Conventional Pump: Postprandial Glycemic Excursions and the Influence of Wear Time. Diabetes Technology and Therapeutics, 2013, 15, 575-579.	4.4	20
90	PS17 - 83. A systematic review and meta-analysis of the diagnostic accuracy of continuous glucose monitoring systems for hypoglycaemia detection. Nederlands Tijdschrift Voor Diabetologie, 2012, 10, 158-158.	0.0	O

#	Article	IF	Citations
91	Sequential Intensification of Metformin Treatment in Type 2 Diabetes With Liraglutide Followed by Randomized Addition of Basal Insulin Prompted by A1C Targets. Diabetes Care, 2012, 35, 1446-1454.	8.6	145
92	Continuous glucose monitoring: coming of age?. European Journal of Endocrinology, 2012, 166, 1-4.	3.7	10
93	Rate of Hypoglycemia in Insulin-Treated Patients with Type 2 Diabetes Can Be Predicted from Glycemic Variability Data. Diabetes Technology and Therapeutics, 2012, 14, 1008-1012.	4.4	106
94	Tu1502 Longitudinal Monitoring of Lipase and Amylase in Adults With Type 2 Diabetes and Obesity: Evidence From Two Phase 3 Randomized Clinical Trials With the Once-Daily GLP-1 Analog Liraglutide. Gastroenterology, 2012, 142, S-850-S-851.	1.3	21
95	The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis. Critical Care, 2011, 15, R205.	5.8	56
96	PS12 - 62. Continuous glucose monitoring accuracy assessed at home is seemingly better than when assessed at the clinical research centre. Nederlands Tijdschrift Voor Diabetologie, 2011, 9, 133-133.	0.0	0
97	No Relevant Relationship between Glucose Variability and Oxidative Stress in Well-Regulated Type 2 Diabetes Patients. Journal of Diabetes Science and Technology, 2011, 5, 86-92.	2.2	48
98	A Decrease in Glucose Variability Does Not Reduce Cardiovascular Event Rates in Type 2 Diabetic Patients After Acute Myocardial Infarction. Diabetes Care, 2011, 34, 855-857.	8.6	79
99	Insulin Degludec in Type 1 Diabetes: A randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care, 2011, 34, 661-665.	8.6	156
100	Glucose variability is associated with intensive care unit mortality*. Critical Care Medicine, 2010, 38, 838-842.	0.9	916
101	Hypoglycemia is associated with intensive care unit mortality*. Critical Care Medicine, 2010, 38, 1430-1434.	0.9	172
102	Premeal Injection of Rapid-Acting Insulin Reduces Postprandial Glycemic Excursions in Type 1 Diabetes. Diabetes Care, 2010, 33, 2152-2155.	8.6	75
103	Glucose Variability; Does It Matter?. Endocrine Reviews, 2010, 31, 171-182.	20.1	364
104	A Patient-level Analysis of Efficacy and Hypoglycaemia Outcomes Across Treat-to-target Trials with Insulin Glargine Added to Oral Antidiabetes Agents in People with Type 2 Diabetes. European Endocrinology, 2010, 10, 23.	1.5	11
105	Glucose Sensing Issues for the Artificial Pancreas. Journal of Diabetes Science and Technology, 2008, 2, 732-734.	2.2	1
106	Combining Insulin Pumps and Continuous Glucose Monitors; Where Are We to Go from Here?. Journal of Diabetes Science and Technology, 2008, 2, 261-262.	2,2	0
107	Relationship Between Interstitial And Blood Glucose in Type 1 Diabetes Patients: Delay And The Push-Pull Phenomenon Revisited. Diabetes Technology and Therapeutics, 2007, 9, 169-175.	4.4	48
108	A Critical Appraisal of the Continuous Glucose-Error Grid Analysis. Diabetes Care, 2006, 29, 1805-1811.	8.6	62

#	Article	IF	CITATIONS
109	Will Long Acting Insulin Analogs Influence the Use of Insulin Pump Therapy in Type 1 Diabetes?. Current Diabetes Reviews, 2005, 1, 23-26.	1.3	1
110	Comparison of a Needle-Type and a Microdialysis Continuous Glucose Monitor in Type 1 Diabetic Patients. Diabetes Care, 2005, 28, 2871-2876.	8.6	105
111	Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Injections: The impact of baseline A1c. Diabetes Care, 2004, 27, 2590-2596.	8.6	222
112	Nocturnal hypoglycaemia in type 1 diabetes?consequences and assessment. Diabetes/Metabolism Research and Reviews, 2004, 20, S43-S46.	4.0	17
113	Improved glycaemic control in type 1 diabetes patients following participationper se in a clinical trial?mechanisms and implications. Diabetes/Metabolism Research and Reviews, 2003, 19, 357-362.	4.0	28
114	A Randomized Trial of Continuous Subcutaneous Insulin Infusion and Intensive Injection Therapy in Type 1 Diabetes for Patients With Long-Standing Poor Glycemic Control. Diabetes Care, 2002, 25, 2074-2080.	8.6	174
115	Adverse side effects of dexamethasone in surgical patients. The Cochrane Library, 0, , .	2.8	40